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Abstract
Background: Probiotic bacteria are suggested to play a role in the maintenance of oral health. Such health promoting 
bacteria are added to different commercial probiotic products. The aim of the study was to investigate the ability of a 
selection of lactobacilli strains, used in commercially available probiotic products, to inhibit growth of oral mutans 
streptococci and C. albicans in vitro.
Methods: Eight probiotic lactobacilli strains were tested for growth inhibition on three reference strains and two 
clinical isolates of mutans streptococci as well as two reference strains and three clinical isolates of Candida albicans 
with an agar overlay method.
Results: At concentrations ranging from 109 to 105 CFU/ml, all lactobacilli strains inhibited the growth of the mutans 
streptococci completely with the exception of L. acidophilus La5 that executed only a slight inhibition of some strains at 
concentrations corresponding to 107 and 105 CFU/ml. At the lowest cell concentration (103 CFU/ml), only L. plantarum 
299v and L. plantarum 931 displayed a total growth inhibition while a slight inhibition was seen for all five mutans 
streptococci strains by L. rhamnosus LB21, L. paracasei F19, L. reuteri PTA 5289 and L. reuteri ATCC 55730. All the tested 
lactobacilli strains reduced candida growth but the effect was generally weaker than for mutans streptococci. The two 
L. plantarum strains and L. reuteri ATCC 55730 displayed the strongest inhibition on Candida albicans. No significant 
differences were observed between the reference strains and the clinical isolates.
Conclusion: The selected probiotic strains showed a significant but somewhat varying ability to inhibit growth of oral 
mutans streptococci and Candida albicans in vitro.
Background
Probiotic bacteria, defined as "live microorganisms which
when administered in adequate amounts confer a health
benefit on the host" (FAO/WHO 2001), are suggested to
play a role in the maintenance of oral health [1,2]. Such
health promoting bacteria are added to different com-
mercial dairy products such as milk, cheese and yogurt as
well as chewing gums and fruit drinks. Possible actions of
probiotic bacteria in the oral environment are competi-
tion of binding sites, production of antimicrobial sub-
stances and activation and regulation of the immune
response [3]. Bacterial antagonism may occur when
growth of one bacterial species is hampered by compo-
nents produced by another species. Lactic acid bacteria
produce antimicrobial components [4,5] and some have
the ability to produce hydrogen peroxide (H2O2) that can
be toxic to organisms producing little or no H2O2-scav-
enging enzymes.
Molecular analyses of the oral microbiota in preschool
children have shown that Streptococcus mutans is signifi-
cantly associated with early childhood caries [6]. Candida
albicans is a persistent member of the oral microbiota in
children with caries [7] with a substantial growth
response to sucrose exposure [8]. C. albicans produce
organic acids like pyruvate and acetate and are consid-
ered to have a significant contribution to caries pathoge-
nisis [9]. Lactobacilli play a significant role in the oral
ecosystem and can be linked with oral disease as well as
oral health [10]. Since the discovery by Polonskaya [11]
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that L. acidophilus inhibits growth of certain streptococci
in vitro, clinical studies have confirmed that probiotic lac-
tobacilli can reduce the counts of salivary mutans strep-
tococci after ingestion of L. rhamnosus GG [12,13] and L.
reuteri [14-16]. Furthermore, naturally occurring Lacto-
bacillus species, including L. paracasei, L. plantarum and
L. rhamnosus, may inhibit growth of laboratory strains of
mutans streptococci as well as subject's autologous
mutans streptococci in vitro [17]. Hatakka et al [18] found
that a cheese containing a mixture of probiotic bacteria
decreased the salivary count of C. albicans in a random-
ized controlled trial among elderly.
The aim of the present study was to investigate the abil-
ity of a selection of lactobacilli strains, used in commer-
cially available probiotic products, to inhibit growth of
mutans streptococci and C. albicans in vitro. The null
hypothesis tested was that none of the lactobacilli strains
would differ significantly from the other.
Methods
Lactobacilli strains and cultivation
Eight strains of probiotic lactobacilli (L. plantarum 299v,
L. plantarum 931,  L. rhamnosus GG ATCC 53103, L.
rhamnosus  LB21,  L. paracasei F19 and L. reuteri PTA
5289, L. reuteri ATCC 55730 and L. acidophilus La5) used
in different probiotic products were selected (Table 1).
The bacteria were provided by the different producers in
pure forms (frozen suspensions or lyophilized) except for
L. acidophilus La5 that was isolated from A-fil® (Arla Ltd,
Stockholm, Sweden). The strains were characterized by
the API 50 CH system (BioMérieux® SA, Marcy-l 'Etoile,
France) to confirm their identity. The bacteria were ini-
tially cultured for 16-20 h on MRS agar (de Man, Rogosa,
Sharpe, Oxid, Hampshire, England). A distinct colony of
each bacterium was then transferred to 4.5 ml MRS broth
for further 16-20 h of incubation.
Mutans streptococci, candida strains and cultivation
Five strains of mutans streptococci (MS) including both
laboratory reference strains (S. mutans NCTC 10449, S.
mutans Ingbritt, and S. sobrinus OMZ176) and clinical
isolates (S. mutans P1:27 and S. mutans P2:29) were cul-
tured on blood agar plates (Columbia Blood Agar Base,
Alpha BioScience, Baltimore, USA) supplemented with
5% horse blood during 16-20 hours and on the following
day, pure colonies of each bacterium were transferred to 2
ml Todd-Hewitt broth (Oxid, Hampshire, England) and
incubated for another 16-20 hours. Five strains of Can-
dida albicans including both reference strains (C. albi-
cans ATCC 28366, C. albicans ATCC 10231) and clinical
isolates (C. albicans 1957, C. albicans 3339 and C. albi-
cans GDM8) were cultured on Difco™ Sabourad Maltose
Agar (Becton, Dickinson and Complany, Sparks, USA)
over night and the following day, pure colonies of each
yeast were transferred to 2 ml Difco™ Sabourad Maltose
broth and incubated for 16-20 hours. The C. albicans
strains were characterized by the API Candida (Bio-
Mérieux® SA, Marcy-l'Etoile, France). Culturing of lacto-
bacilli and mutans streptococci were performed in
anaerobic atmosphere (10% H2, 5% CO2 and 85% N2) in
an anaerobe chamber at 37°C, while culturing of C. albi-
cans was performed under aerobic conditions at 37°C.
Agar overlay interference tests
The broth cultures of lactobacilli were serial diluted in
tenfold steps. The optical density (OD) was measured at
630 nm using a spectrophotometer at dilution 10-1 (Ultro-
spec 100 pro, Visible Spectrophotometer, Biochrom Ltd.
Cambridge, England). Undiluted suspension and cell sus-
pensions corresponding to approximately 109, 107, 105,
and 103 CFU/ml were used in the inhibition experiments.
One ml of each lactobacilli suspension was added into 24
ml molten sterile MRS agar (ca 45°C) and plates were
casted. When the agar was set, the plates were incubated
at 37°C over night in anaerobic atmosphere. The next day,
a second agar layer of 23 ml molted M17 agar supple-
mented with 10% sterile filtered lactose (May and Baker,
Dagenham, England) was casted on top of the MRS agar
with grown lactobacilli. The plates were allowed to dry
for 3 hours at room temperature. Broth cultures of MS
Table 1: Probiotic lactobacilli strains, producer and products used in the present experiments.
Strain Producer Product
L. plantarum 299v Probi AB, Lund, Sweden Fruit drink
L. plantarum 931 Essum, Umeå, Sweden Fruit drink
L. rhamnosus GG ATCC 53103 Valio Ltd, Helsinki, Finland Yogurt
L. rhamnosus LB21 Essum, Umeå, Sweden Yogurt
L. paracasei F19 Arla Ltd, Stockholm, Sweden Yogurt, Porridge, Gruel
L. reuteri PTA 5289 BioGaia, Stockholm, Sweden Chewing gum, Tablets
L. reuteri ATCC 55730 BioGaia, Stockholm, Sweden Chewing gum, Gruel, Drops, Tablets
L. acidophilus La5 Arla Ltd, Stockholm, Sweden Fermented milkHasslöf et al. BMC Oral Health 2010, 10:18
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grown for 16-20 hours in Todd-Hewitt broth were diluted
in the same medium and the OD was measured at 500 nm
and adjusted to 0.2. The suspensions of MS were stamped
on the plates with Steer's replicator (CMI-Promex ICN,
Pedricktown, USA). The plates were left at room temper-
ature for 1 hour to dry and were subsequently incubated
over night at 37°C in the anaerobe chamber. T o test the
susceptibility of C. albicans, 24 ml Difco™ Sabourad Malt-
ose Agar (SAB) was casted on top of the MRS agar with
grown lactobacilli. Broth cultures of C. albicans grown
for 16-20 h in Difco™ Sabourad Maltose Broth were
diluted in the same medium and the OD was measured at
500 nm and adjusted to 0.2. The suspensions were then
stamped on the plates in the same way as MS (see above).
The plates inoculated with C. albicans were incubated in
air at 37°C. As controls, the MS and C. albicans strains
were stamped onto agar plates without lactobacilli within
the first agar layer.
All assays were made in duplicate and each experiment
was repeated on three different occasions. The results of
the agar overlay tests were categorized as follows accord-
ing to Simark-Mattsson et al. [17]: Score 0 = complete
inhibition (no visible colonies), Score 1 = slight inhibition
(at least one visible colony but definitely smaller amounts
then in the control plate), and Score 2 = no inhibition (the
same growth as on the control plate). The evaluation of
the plates was performed by two independent observers,
in case of disagreement a consensus was reached after
discussion.
pH-measurements
As an estimation of the lactobacilli acid production, the
surface pH of the MRS plates with M17 and SAB agar was
determined before and after the final incubation of each
lactobacilli strain but without mutans streptococci or
candida. A pH-meter (Seven Easy pH, Mettler-Toledoo
GmbH, Schwerzenbach, Switzerland) equipped with a
flat electrode was used and the mean of two measure-
ments was calculated.
Statistical method
The data were processed with the SPSS software (version
17.0, Chicago Ill, USA) and subjected to chi-square tests.
A p-value < 0.05 was considered as statistically signifi-
cant.
Results
Characterization of lactobacilli and Candida albicans
Both L. plantarum strains as well as the L. acidophilus
La5, L. paracasei F19 strains were identified by the API
50 CH system without difficulty. The two L. reuteri
strains gave a biochemical profile interpreted as L. fer-
mentum. None of the L. rhamnosus strains were fully
identified by the system. All five candida strains were
completely identified as C. albicans by the API Candida
assay.
Growth inhibition of mutans streptococci
The results of the growth inhibition assay are summa-
rized in Table 2. At concentrations ranging from 109 to
105 CFU/ml, all lactobacilli strains inhibited the growth of
the MS strains completely with the exception of L. acido-
philus La5 that executed only a slight inhibition of some
strains at concentrations corresponding to 107 and 105
CFU/ml.  L. acidophilus La5 had a statistically signifi-
cantly weaker inhibition capacity in comparison with the
other probiotic strains (p < 0.05). At the lowest cell con-
centration (103 CFU/ml), only L. plantarum 299v and L.
plantarum 931 displayed a total growth inhibition while a
slight inhibition was seen for all five MS strains by L.
rhamnosus LB21, L. paracasei F19, L. reuteri PTA 5289
and  L. reuteri ATCC 55730. L. rhamnosus GG ATCC
53103 diluted to 103 CFU/ml inhibited the growth slightly
for three of the five MS strains (S. mutans NCTC 10449,
S. sobrinus OMZ176 and S. mutans P1:27) while low con-
centrations of L. acidophilus La5 did not affect MS
growth. In general, no significant differences in growth
inhibition were observed between the reference strains
and the oral isolates.
Growth inhibition of Candida albicans
All the tested lactobacilli strains reduced candida growth
but the effect was generally weaker than for mutans
streptococci. Since an identical inhibition pattern was
displayed for all candida strains, the results of the assays
for only one of them are displayed in Table 3. At concen-
trations 109 and 107 CFU/ml, all lactobacilli except L. aci-
dophilus La5 and L. reuteri PTA 5289 inhibited the five
candida strains completely. At 105 CFU/ml, L. rhamnosus
LB21, L. rhamnosus GG ATCC 53103, L. paracasei F19
and L. reuteri PTA 5289 displayed a slight inhibition, L.
acidophilus La5 showed no inhibition at all while L. plan-
tarum 299v, L. plantarum 931 and L. reuteri ATCC 55730
executed a total inhibition. At the lowest cell concentra-
tion, no inhibition was recorded except for the two L.
plantarum strains.
pH-measurements
The initial pH on the surface of the M17 and SAB agar
plates were 6.8 and 5.8, respectively. After incubation, the
pH decreased in all plates inoculated with lactobacilli and
varied between 3.7 and 5.3 in the plates containing 103
CFU/ml (Table 4). L. acidophilus La5 displayed the high-
est pH values while the lowest values were recorded for
the L. plantarum strains.
Discussion
The predominant strategy for caries prevention relies on
influencing the re- and demineralisation processes,Hasslöf et al. BMC Oral Health 2010, 10:18
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mainly by using fluorides but also other factors involved
in the caries process may be targeted [19]. One alterna-
tive could be to promote colonization of caries inhibiting
bacteria and in this aspect, probiotic bacteria constitute a
novel concept that needs further exploration. This in
vitro study was performed to compare the effect of eight
commercial probiotic lactobacilli strains on growth inhi-
bition of mutans streptococci and C. albicans. We
selected these particular lactobacilli strains because they
are found in dairy products, fruit drinks, drops, gruels,
chewing gums and tablets on the market. The test panel
of mutans streptococci and yeast contained both refer-
ence strains and clinical isolates. Candida albicans is the
most commonly isolated candida species in the oral cav-
ity and constitute up to 80% of the clinical isolates [20].
Furthermore, candida has been ascribed a significant pre-
dictive value for dental caries in children [21]. The major-
ity of the lactobacilli strains were fully identified with
biochemical analysis using the API 50 CH system while a
satisfactory identification of the L. reuteri and L. rhamno-
sus strains would require molecular genetic methods [22].
The agar overlay method was considered suitable for
the research question since the method can test the
inhibitory effect on multiple strains on a single plate. The
method has earlier been used to demonstrate the in vitro
growth inhibition of different isolates of lactobacilli on
pathogenic bacteria in the female urogenital region [23]
Table 2: Growth inhibition of mutans streptococci strains by selected probiotic lactobacilli at different cell concentrations.
Mutans streptococci (inhibition score)
Lactobacilli CFU/ml Ingbritt NCTC
10449
OMZ176 P1:27 P2:29
L. plantarum 299v 103-109 00 00 0
L. plantarum
931
103-109 00 00 0
L. rhamnosus GG 105-109 00 00 0
ATCC 53103 103 01 11 0
L. rhamnosus 105-109 00 00 0
LB21 103 11 11 1
L. paracasei 105-109 00 00 0
F19 103 11 11 1
L. reuteri 105-109 00 00 0
PTA5289 103 11 11 1
L. reuteri 105-109 00 00 0
ATCC 55730 103 11 11 1
L. acidophilus 109 00 00 0
La5 * 107 01 10 1
105 11 11 1
103 22 22 2
Inhibition scores; 0 = total inhibition; 1 = slight inhibition; 2 = no inhibition.
* p < 0.05, chi-square test.
Table 3: Growth inhibition of Candida albicans ATCC 28366 
by selected probiotic lactobacilli at different cell 
concentrations.
Strain Cell concentration (CFU/ml)
109 107 105 103
L. plantarum 299v 0 0 0 1
L. plantarum 931 0 0 0 1
L. rhamnosus GG ATCC 53103 0 0 1 2
L. rhamnosus L B 2 1 0012
L. paracasei F 1 9 0012
L. reuteri PTA 5289 1 1 1 2
L. reuteri ATCC 55730 0 0 0 2
L. acidophilus L a 5 1122
Inhibition scores; 0 = total inhibition; 1 = slight inhibition; 2 = no 
inhibition.Hasslöf et al. BMC Oral Health 2010, 10:18
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and to study the inhibitory effect of alpha-hemolytic
streptococci on the otitis media pathogens Streptococcus
pneumoniae,  Haemophilus influenzae and  Moraxella
catarrhalis [24]. Kõll et al [25] used the deferred antago-
nism method to test the inhibitory capacity against
mutans streptococci and C. albicans. In that method the
lactobacilli are stab-inoculated on the surface of the bot-
tom agar and pathogen suspensions are poured over the
macrocolonies of lactobacilli. After incubation the width
of the inhibition zones are measured. The main advan-
tage with the deferred antagonism method is the more
exact outcome while the agar overlay method enables
assessment of different cell concentrations. Thus, the
methods may be regarded as complements to each other.
With the exception of L. acidophilus, the present probi-
otic strains displayed strong inhibitory capacities against
both the reference strains and the oral mutans strepto-
cocci isolates and these results were mainly in agreement
with the recent observations of Simark-Mattsson and
coworkers [17]. The findings concerning the candida
strains were however novel and showed an even larger
variation between the lactobacilli strains and only three
of the eight tested strains exhibited strong inhibitory
capacity. These results were in disagreement to Kõll et al
[25] who failed to demonstrate inhibition of Candida
albicans 048 (wild-type). This could due to the method
used in the experiments or the fact that the tested can-
dida strain were more resistant then our reference strains
and clinical isolates. The production of bacteriocins can
be different in different systems and the ability to diffuse
through the agar. Since significant growth inhibiting dif-
ferences between the probiotic lactobacilli were noted,
the null hypothesis was rejected. Similar strain-depen-
dant differences have previously been observed concern-
ing the metabolic capacity to form acids from dietary
sugars that differs significantly between various probiotic
strains [26,27].
The final pH in the medium has been suggested to be
an important factor for growth inhibition, either directly
or due to the production of bacteriocins at low pH [28].
We found a similar tendency in the present experiments;
the lactobacilli strains that caused the lowest pH after
incubation were also most effective in inhibiting MS and
candida growth. The weakest inhibition of both mutans
streptococci and C.albicans was displayed by L acidophi-
lus La5 which also had the weakest acid production in
both systems. In the agar overlay method the lactobacilli
is grown inside the MRS-agar and it is possible that this
particular system not is optimal for L. acidophilus La5.
The inhibitory potential may be different, for better or for
worse, in other test system or in vivo. However, also some
bacteria with fairly weak acid production, such as L. reu-
teri  ATCC 55730, proved to be effective against both
mutans streptococci and candida. This indicates that
other inhibitory substances also may be involved in the
process with H2O2 being among the primary metabolites
with inhibitory capacity against microbial pathogens [29].
The importance of H2O2 production for health can be
illustrated in bacterial vaginosis, since lack of lactobacilli
with such production seems to be associated with an
altered composition of the vaginal flora resulting in a
massive anaerobic overgrowth [30]. Tano et al. [31] con-
cluded that the inhibitory effect of alpha-hemolytic strep-
tococci on otitis media pathogens most likely was due to
their H2O2 production. The antimicrobial glycerol deriva-
tive reuterin is another example of a growth inhibitory
substance produced by L. reuteri [32] that may be
involved in the reduction of mutans streptococci in saliva
[14,15] as well as beneficial influences on gingivitis [33]
and inflammatory mediators in gingival crevicular fluid
[34]. Although any conclusion from in vitro studies must
be drawn with caution, our findings provide some further
support to the hypothesis that probiotic lactobacilli may
influence the homeostasis and microbial profile in the
oral cavity.
Conclusion
The present in vitro study showed that commercial probi-
otic lactobacilli could inhibit growth of reference strains
and oral isolates of mutans streptococci and candida but
the capacity differed significantly between the strains.
Further clinical studies are needed to verify whether or
not the observed differences can play a role in the com-
plex oral biofilm.
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